Health News Releases

  • Today September 1
May 28, 08:44
Takeda and Nature Announce Call for Applications Now Open for 2026 Innovators in Science Award
Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=54259352&newsitemid=20250527716937&lan=en-US&anchor=TSE%3A4
May 27, 17:06
World-Leading Cancer Center, The Royal Marsden NHS Foundation Trust, Using AI to Push Boundaries of Cancer Research With NTT DATA and CARPL.ai
The Royal Marsden NHS Foundation Trust (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.royalmarsden.nhs.uk%2F&esheet=54258962&newsitemid=20250527348807&lan=en-US&anchor=The+Roya
May 25, 14:25
BeiGene Presents Pioneering Cancer Research at ASCO 2025 - Redefining Treatment Across Hematology and Solid Tumors
BeiGene (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.beigene.com%2F&esheet=54258273&newsitemid=20250522213317&lan=en-US&anchor=BeiGene&index=1&md5=b2e553cdb745c6a1895871c2f51
May 23, 13:55
Rubedo Life Sciences Announces First Patient Dosed with Lead Drug Candidate RLS-1496, the First GPX4 Modulator Targeting Pathologic Senescent Cells To Enter Phase 1 Clinical Trial
Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced
May 23, 11:30
Merck Showcases Innovation in Advanced Cancers and Rare Tumors at ASCO 2025
Merck, a leading science and technology company, today announced the presentation of new oncology data across more than 12 tumor types at the 2025 American Society of Clinical Oncology (ASCO) Annual M
May 23, 11:30
CCM Biosciences Announces Presentation of Data on its First-In-Class AML Drug Program at ASCO 2025
CCM Biosciences (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3973906-1%26h%3D3084432827%26u%3Dhttps%253A%252F%252Fwww.ccm-bio.com%25
May 23, 10:45
CCM Biosciences Announces Presentation of Data on its First-In-Class NSCLC Drug Program at ASCO 2025
CCM Biosciences (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3973906-1%26h%3D3084432827%26u%3Dhttps%253A%252F%252Fwww.ccm-bio.com%25
Novotech, a globally recognized full-service clinical research organization (CRO) and scientific adv
May 22, 15:25
Novotech Honored with Triple Win in 2025 Pharmaceutical Technology Excellence Awards
Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory partner for biotech and small- to mid-sized pharmaceutical companies, is proud to announce its
May 22, 08:40
Merck Presents Positive Phase 2 Data for Enpatoran Demonstrating Reduction in Disease Activity in Patients with Cutaneous Lupus Erythematosus (CLE) and Systemic Lupus Erythematosus (SLE) with Active Lupus Rash
Not intended for UK-, US- or Canada-based media Merck, a leading science and technology company, today announced positive data on enpatoran, an investigational, oral, novel TLR7/8 inhibitor, demons
May 18, 15:15
Fujirebio Receives Marketing Clearance for Lumipulse® G pTau 217/ β-Amyloid 1-42 Plasma Ratio In-vitro Diagnostic Test as an Aid to Identify Patients With Amyloid Pathology Associated With Alzheimer’s Disease
Fujirebio today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio in-vitro diagnostic (IVD) te
May 18, 15:00
Everyday Care in Action: Thousands of Kenvue Employees Come Together Across 21 Markets to Help Advance Healthier Communities
Kenvue Inc. (NYSE: KVUE), the maker of iconic brands such as Neutrogena®, Listerine®, Aveeno®, and Tylenol®, today announced its global community engagement efforts in celebration of Kenvue Cares Week
May 18, 12:55
The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 1
Takeda (TSE: 4502/NYSE:TAK (https://www.takeda.com/investors/overview/)) today announced that the New England Journal of Medicine (https://www.nejm.org/doi/full/10.1056/NEJMoa2405847) published data f
May 16, 17:20
GSK to acquire efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of steatotic liver disease (SLD)
GSK plc (LSE/NYSE: GSK) and Boston Pharmaceuticals, a leading clinical stage biopharmaceutical company developing highly targeted therapies for patients with serious liver diseases, today announced th
Image created by Clara Leibenguth for Stanford University; featured on cover of May 2025 issue of Na
May 16, 17:00
Rubedo Life Sciences’ Drug Discovery Platform, ALEMBIC™, Helps Identify Senescent or “Zombie” Neurons in New Study Linking Neuropathic Pain and Aging Published in Peer-Reviewed Scientific Journal Nature Neuroscience
Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced
May 16, 15:00
Ecolab Life Sciences Opens New State-of-the-Art Bioprocessing Applications Laboratory in Pennsylvania, US
Ecolab Life Sciences has officially opened its new US Bioprocessing Applications Laboratory in King of Prussia, Pennsylvania. The new facility is designed to support biopharma customers with applic
71.4% of MetaXplore™ reports from 4,616 patients identified actionable results
May 16, 14:35
Microba Announces Landmark GI Study Results From Over 4,600 Patients
Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”), a precision microbiome company, today announces preliminary results from the analysis of over 4,600 MetaXplore™ GI Plus (https://
Dr. Jerome Kim, Director General of IVI (left), standing next to TriLink’s Chief Commercial Officer,
May 15, 16:30
TriLink BioTechnologies® and the International Vaccine Institute Sign a Memorandum of Understanding to Support the Development of mRNA-based Vaccines
Today, TriLink BioTechnologies (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.trilinkbiotech.com%2F&esheet=54254971&newsitemid=20250514331075&lan=en-US&anchor=TriLink+BioTechno
Novotech is proud to announce it has been awarded the Citeline CRO Partnership of the Year Award in
May 14, 13:30
Novotech Wins Citeline CRO Partnership of the Year Award for Strategic Collaboration with Tune Therapeutics
Novotech a globally recognized full-service clinical research organization (CRO) and scientific advisory company, is proud to announce it has been awarded the Citeline CRO Partnership of the Year Awar
HistoSonics Edison Histotripsy System
May 13, 15:30
HistoSonics Secures First Major Insurance Coverage for Non-Invasive Histotripsy Treatment for Liver Tumors With Blue Cross Blue Shield of Michigan
HistoSonics (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fhistosonics.com%2F&esheet=54252813&newsitemid=20250512714050&lan=en-US&anchor=HistoSonics&index=1&md5=41ec7eed6a70eb897ae
May 09, 15:10
BeiGene Announces First Quarter 2025 Financial Results and Business Updates
BeiGene (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.beigene.com%2F&esheet=54250156&newsitemid=20250507583971&lan=en-US&anchor=BeiGene&index=1&md5=4f57ade9dfc9fe1fd6bc4495287
May 09, 14:30
Novotech Analysis Highlights Rising Clinical Development Efforts for Obesity Treatments
Novotech, a leading global clinical research organization (CRO) and scientific advisory partner, has published a report analyzing recent trends in obesity-related clinical trials. The report shows tha
WHOOP Unveils Next Generation WHOOP® 5.0 and WHOOP® MG
May 09, 13:50
WHOOP Unveils WHOOP® 5.0 and WHOOP® MG: Powerful New Devices with Breakthrough Health and Longevity Features
WHOOP (https://www.whoop.com/ie/en/), the human performance company, today introduces WHOOP 5.0 and WHOOP MG — two next-generation wearables designed to unlock a new approach to personal health and lo
May 09, 13:40
GC Aesthetics® Strengthens Board of Directors with Strategic Appointments
GC Aesthetics® (GCA), a privately-held medical technology company providing aesthetic and reconstruction solutions for global healthcare markets is pleased to announce the appointment of Mr. Luigi Fer
Professor Sebastian Johnston
May 08, 17:10
Results from the VirTus Respiratory Research Ltd Human Rhinovirus Challenge Model Used to Advance Altesa BioSciences’ Lead Medicine into Advanced Clinical Trials
VirTus Respiratory Research Ltd, a leading respiratory-focused contract research organisation (CRO), today announced that results from their human rhinovirus challenge model in patients with chronic o
May 08, 17:06
Takeda Announces FY2024 Full Year Results and FY2025 Outlook Reflecting Growth & Launch Products Momentum, Strong Cash Flow Generation and Late-Stage Pipeline Progress
Takeda (TOKYO:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Fstock-information%2F&esheet=54244498&newsitemid=20250427084429&lan=en-US&anc
25 per page50 per page75 per page100 per page